Breaking: Abcam to be Acquired by Danaher; Setback for NovoCure
- August 28th, 2023
- 487 views
Abcam plc (Nasdaq: ABCM) has agreed to be acquired by Danaher Corporation (NYSE: DHR) for $24.00 per share in cash.
The transaction has received unanimous approval from both Abcam's and Danaher's Boards of Directors.
In pre-market, $ABCM is trading at $23.45, up $0.09 (+0.39%), while $DHR is at $254.75, showing a decline of $0.78 (-0.31%).
In another development, NovoCure Limited (Nasdaq: NVCR) announced that its phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial evaluating Tumor Treating Fields (TTFields) alongside paclitaxel in patients with platinum-resistant ovarian cancer has not met its primary endpoint of overall survival (OS) in the final analysis.
$NVCR is currently trading at $18.00 in pre-market, down $11.77 (-39.54%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Watch: What to Expect from Walt Disney, AppLovin, and DoorDash
August 03rd, 2025Key Earnings on Deck: AMD, Caterpillar, and Amgen to Post Q2 Results
August 03rd, 2025Palantir, Freshpet, and ONEOK Set to Unveil Q2 Earnings
August 03rd, 2025Herbal Works Inc. Announces Three Signature Scents of CBD Bath Bombs
August 01st, 2025
Member Login